Ankylosing spondylitis

1. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in spondylarthropathies: a systematic literature review. Ann Rheum Dis. 2008 Jul;67(7):955-9.[Abstract]

2. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006 Jun;20(3):451-71.[Abstract]

3. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361-8.[Abstract][Full Text]

4. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct;34(10):1218-27.[Abstract][Full Text]

5. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic. 1990 Feb;57(2):85-9.[Abstract]

6. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83.[Abstract][Full Text]

7. Navarro-Compán V, Benavent D, Capelusnik D, et al. ASAS consensus definition of early axial spondyloarthritis. Ann Rheum Dis. 2023 Jun 15: ard-2023-224232.[Abstract]

8. Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977 Jun 13;237(24):2613-4.[Abstract]

9. Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006 Feb;54(2):569-78.[Abstract][Full Text]

10. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009 Jun;68(6):784-8.[Abstract]

11. Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol. 1989 Feb;16(2):192-7.[Abstract]

12. Shih YJ, Yang YH, Lin CY, et al. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease. Pediatr Rheumatol Online J. 2019 Aug 23;17(1):58.[Abstract][Full Text]

13. Zanwar A, Phatak S, Aggarwal A. Prospective validation of the Juvenile Spondyloarthritis Disease Activity Index in children with enthesitis-related arthritis. Rheumatology (Oxford). 2018 Dec 1;57(12):2167-71.[Abstract][Full Text]

14. Weiss PF, Klink AJ, Behrens EM, et al. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2011 Sep;63(9):1307-12.[Abstract][Full Text]

15. Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015 Nov;34(11):1839-46.[Abstract]

16. Stone M, Warren RW, Bruckel J, et al. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum. 2005 Jun 15;53(3):445-51.[Abstract][Full Text]

17. Lee W, Reveille JD, Weisman MH. Women with ankylosing spondylitis: a review. Arthritis Rheum. 2008 Mar 15;59(3):449-54.[Abstract][Full Text]

18. Chatzikyriakidou A, Voulgari PV, Drosos AA. What is the role of HLA-B27 in spondyloarthropathies? Autoimmun Rev. 2011 Jun;10(8):464-8.[Abstract]

19. Reveille JD, Hirsch R, Dillon CF, et al. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum. 2012 May;64(5):1407-11.[Abstract][Full Text]

20. Hanson A, Brown MA. Genetics and the causes of ankylosing spondylitis. Rheum Dis Clin North Am. 2017 Aug;43(3):401-14.[Abstract][Full Text]

21. Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016 May;48(5):510-8.[Abstract][Full Text]

22. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018 Mar;30(2):137-43.[Abstract][Full Text]

23. Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014 Apr;53(4):650-7.[Abstract][Full Text]

24. Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012 Jun;64(6):905-10.[Abstract][Full Text]

25. Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001 Mar;28(3):554-9.[Abstract]

26. Alamanos Y, Papadopoulos NG, Voulgari PV, et al. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford). 2004 May;43(5):615-8.[Abstract][Full Text]

27. De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol. 2007 Jan-Feb;36(1):14-21.[Abstract]

28. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis. 2005 Oct;64(10):1431-5.[Abstract][Full Text]

29. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58-67.[Abstract]

30. Bohn R, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol. 2018 Mar-Apr;36(2):263-74.[Abstract][Full Text]

31. Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? Arthritis Rheum. 1992 Dec;35(12):1476-82.[Abstract]

32. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol. 2000 Jul;12(4):239-47.[Abstract]

33. Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol. 1993 Nov;20(11):1900-4.[Abstract]

34. Will R, Edmunds L, Elswood J, et al. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol. 1990 Dec;17(12):1649-52.[Abstract]

35. Moll JM, Wright V. New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis. 1973 Jul;32(4):354-63.[Abstract][Full Text]

36. Haroon NN, Paterson JM, Li P, et al. Increasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of AS. BMJ Open. 2014 Dec 15;4(12):e006634.[Abstract][Full Text]

37. Braun J, Sieper J. Inception cohorts for spondyloarthropathies [in German]. Z Rheumatol. 2000 Apr;59(2):117-21.[Abstract]

38. Hamersma J, Cardon LR, Bradbury L, et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum. 2001 Jun;44(6):1396-400.[Abstract][Full Text]

39. Brophy S, Hickey S, Menon A, et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheumatol. 2004 Sep;31(9):1775-8.[Abstract]

40. Kollnberger S, Bowness P. The role of B27 heavy chain dimer immune receptor interactions in spondyloarthritis. Adv Exp Med Biol. 2009;649:277-85.[Abstract]

41. Kollnberger S, Bird L, Sun MY, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 2002 Nov;46(11):2972-82.[Abstract]

42. Rezaei R, Mostafaei S, Aslani S, et al. Association study between killer immunoglobulin-like receptor polymorphisms and ankylosing spondylitis disease: an updated meta-analysis. Int J Rheum Dis. 2018 Oct;21(10):1746-55.[Abstract]

43. Brown MA. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology (Oxford). 2008 Feb;47(2):132-7.[Abstract]

44. Lee YH, Song GG. Associations between ERAP1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis. Clin Rheumatol. 2016 Aug;35(8):2009-25.[Abstract]

45. Castro-Santos P, Moro-García MA, Marcos-Fernández R, et al. ERAP1 and HLA-C interaction in inflammatory bowel disease in the Spanish population. Innate Immun. 2017 Jul;23(5):476-81.[Abstract][Full Text]

46. Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011 Jul 10;43(8):761-7.[Abstract]

47. Han R, Xia Q, Xu S, et al. Interleukin-23 receptor polymorphism (rs10889677 A/C) in ankylosing spondylitis: meta-analysis in Caucasian and Asian populations. Clin Chim Acta. 2018 Feb;477:53-9.[Abstract]

48. Hu N, Liu D, Zhao N, et al. Lack of association between TNF polymorphism and ankylosing spondylitis susceptibility in HLA-B27-positive population: a meta-analysis. Eur Spine J. 2021 Aug;30(8):2401-8.[Abstract]

49. Khorrampazhouh N, Omranzadeh A, Fazeli B, et al. A systematic review and meta-analysis of clinical studies on ankylosing spondylitis and neutrophil to lymphocyte ratio. Curr Rheumatol Rev. 2022;18(2):160-7.[Abstract]

50. Gao S, Xu T, Liang W, et al. Association of rs27044 and rs30187 polymorphisms in endoplasmic reticulum aminopeptidase 1 gene and ankylosing spondylitis susceptibility: a meta-analysis. Int J Rheum Dis. 2020 Apr;23(4):499-510.[Abstract]

51. Su QY, Zheng JW, Yang JY, et al. Levels of peripheral Th17 cells and Th17-related cytokines in patients with ankylosing spondylitis: a meta-analysis. Adv Ther. 2022 Oct;39(10):4423-39.[Abstract]

52. Zhang T, Yu L, Shao M, et al. Associations between IL-23R gene polymorphism (rs10889677 A/C) and ankylosing spondylitis and rheumatoid arthritis susceptibility: a meta-analysis with trial sequential analysis. Autoimmunity. 2022 Sep;55(6):388-97.[Abstract]

53. Gao M, Li T, Song Z, et al. Relationship between IL1 gene polymorphism and susceptibility to ankylosing spondylitis: an updated and supplemented meta-analysis. Biochem Genet. 2022 Jun;60(3):1025-38.[Abstract]

54. Bai Y, Zhao N, Sun H, et al. Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility in HLA-B27 positive population: a meta-analysis and bioinformatics analysis. Nucleosides Nucleotides Nucleic Acids. 2022;41(4):407-18.[Abstract]

55. Gao S, Liang W, Xu T, et al. Associations of tumor necrosis factor alpha gene polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis based on 35 case-control studies. Immunol Invest. 2022 May;51(4):859-82.[Abstract]

56. Chen M, Li W, Li L, et al. Ankylosing spondylitis disease activity and serum vitamin D levels: a systematic review and meta-analysis. Medicine (Baltimore). 2022 Nov 18;101(46):e31764.[Abstract][Full Text]

57. Deng J, Xu S, Gao X, et al. Red cell distribution width and mean platelet volume in patients with ankylosing spondylitis: a systematic review and meta-analysis. J Clin Rheumatol. 2021 Oct 1;27(7):292-7.[Abstract]

58. Puccetti A, Dolcino M, Tinazzi E, et al. Antibodies directed against a peptide epitope of a Klebsiella pneumoniae-derived protein are present in ankylosing spondylitis. PLoS One. 2017 Jan 30;12(1):e0171073.[Abstract][Full Text]

59. Long F, Wang T, Li Q, et al. Association between Klebsiella pneumoniae and ankylosing spondylitis: a systematic review and meta-analysis. Int J Rheum Dis. 2022 Apr;25(4):422-32.[Abstract]

60. Loddenkemper K, Burmester GR. What is the rank of RANKL in spondylarthritis? Arthritis Rheum. 2008 Mar;58(3):641-4.[Abstract]

61. Vandooren B, Cantaert T, Noordenbos T, et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008 Mar;58(3):718-29.[Abstract]

62. Sieper J, Appel H, Braun J, et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008 Mar;58(3):649-56.[Abstract]

63. Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis. 2007 Jun;66(6):709-11.[Abstract][Full Text]

64. Cruickshank B. Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol. 1956 Jan;71(1):73-84.[Abstract]

65. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis. 1971 May;30(3):213-23.[Abstract][Full Text]

66. Aufdermaur M. Pathogenesis of square bodies in ankylosing spondylitis. Ann Rheum Dis. 1989 Aug;48(8):628-31.[Abstract][Full Text]

67. Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 2006 Jun;54(6):1805-13.[Abstract][Full Text]

68. Chen M, Hu X, Wu M, et al. Serum levels of OPG, RANKL, and RANKL/OPG ratio in patients with ankylosing spondylitis: a systematic review and meta-analysis. Immunol Invest. 2019 Jul;48(5):490-504.[Abstract]

69. Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum. 1999 Nov;42(11):2319-24.[Abstract][Full Text]

70. Toussirot E, Ricard-Blum S, Dumoulin G, et al. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford). 1999 Jan;38(1):21-7.[Abstract][Full Text]

71. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis. 2000 Feb;59(2):135-40.[Abstract][Full Text]

72. François RJ, Neure L, Sieper J, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006 Jun;65(6):713-20.[Abstract][Full Text]

73. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006 Sep;54(9):2845-51.[Abstract][Full Text]

74. François RJ, Gardner DL, Degrave EJ, et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. 2000 Sep;43(9):2011-24.[Abstract][Full Text]

75. Zochling J, Baraliakos X, Hermann KG, et al. Magnetic resonance imaging in ankylosing spondylitis. Curr Opin Rheumatol. 2007 Jul;19(4):346-52.[Abstract]

76. van der Heijde DM, Landewe RB, Ory P, et al. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. EULAR Congress Abstract OP0090. Ann Rheum Dis. 2006;65(suppl II):81.[Full Text]

77. van der Heijde D, Landewe R, Deoadar A, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. EULAR Congress Abstract OP0111. Ann Rheum Dis. 2007;66(suppl II):85.[Full Text]

78. LaSalle SP, Deodhar AA. Appropriate management of axial spondyloarthritis. Curr Rheumatol Rep. 2007 Oct;9(5):375-82.[Abstract]

79. van der Linden SM, Valkenburg HA, de Jongh BM, et al. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984 Mar;27(3):241-9.[Abstract][Full Text]

80. de Winter JJ, van Mens LJ, van der Heijde D, et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016 Sep 1;18(1):196. [Abstract][Full Text]

81. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol.1994 Sep;21(9):1694-8.[Abstract]

82. American College of Radiology. ACR appropriateness criteria: inflammatory back pain: known or suspected axial spondyloarthritis. 2021 [internet publication]. [Full Text]

83. Kim Y, Chee CG, Kim J, et al. Diagnostic performance of plain radiography for sacroiliitis in patients with suspected axial spondyloarthritis: a systematic review and meta-analysis. Acta Radiol. 2021 Apr;62(4):500-9.[Abstract]

84. Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021 Jan 4;372:m4447.[Abstract][Full Text]

85. Jones A, Bray TJP, Mandl P, et al. Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford). 2019 Nov 1;58(11):1955-65.[Abstract][Full Text]

86. Song IH, Carrasco-Fernández J, Rudwaleit M, et al. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis. 2008 Nov;67(11):1535-40.[Abstract]

87. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980-4.[Abstract]

88. van der Heijde D, Bellamy N, Calin A, et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol. 1997 Nov;24(11):2225-9.[Abstract]

89. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994 Dec;21(12):2286-91.[Abstract]

90. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281-5.[Abstract]

91. Ball EJ, Khan MA. HLA-B27 polymorphism. Joint Bone Spine. 2001 Oct;68(5):378-82.[Abstract]

92. Brown MA, Rudwaleit M, Pile KD, et al. The role of germline polymorphisms in the T-cell receptor in susceptibility to ankylosing spondylitis. Br J Rheumatol. 1998 Apr;37(4):454-8.[Abstract][Full Text]

93. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002 Jul;14(4):337-41.[Abstract]

94. Careless DJ, Inman RD. Acute anterior uveitis: clinical and experimental aspects. Semin Arthritis Rheum. 1995 Jun;24(6):432-41.[Abstract]

95. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, et al. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum. 2003 Feb;48(2):523-33.[Abstract][Full Text]

96. Moll JM, Haslock I, Macrae IF, et al. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome. Medicine (Baltimore). 1974 Sep;53(5):343-64.[Abstract]

97. Brown MA, Wordsworth BP, Reveille JD. Genetics of ankylosing spondylitis. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 suppl 28):S43-9.[Abstract]

98. Jones SD, Koh WH, Steiner A, et al. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol. 1996 Mar;23(3):487-90.[Abstract]

99. Li Z, Fu T, Wang Y, et al. Sleep disturbances in ankylosing spondylitis: a systematic review and meta-analysis. Psychol Health Med. 2019 Sep;24(8):911-24.[Abstract]

100. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, et al. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Jan;74(1):65-73.[Abstract][Full Text]

101. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016 Jun 30;374(26):2563-74.[Abstract]

102. Dale K. Radiographic gradings of sacroiliitis in Bechterew's syndrome and allied disorders. Scand J Rheumatol Suppl. 1980;(suppl 32):92-7.

103. Heuft-Dorenbosch L, Landewé R, Weijers R, et al. Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis. 2007 Jan;66(1):92-8.[Abstract][Full Text]

104. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005 May;64(5):659-63.[Abstract][Full Text]

105. Oostveen J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography: a prospective, longitudinal study. J Rheumatol. 1999 Sep;26(9):1953-8.[Abstract]

106. Eshed I, Bollow M, McGonagle DG, et al. MRI of enthesitis of the appendicular skeleton in spondyloarthritis. Ann Rheum Dis. 2007 Dec;66(12):1553-9.[Abstract]

107. Creemers MC, Franssen MJ, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005 Jan;64(1):127-9.[Abstract][Full Text]

108. Cammisa M, De Serio A, Guglielmi G. Diffuse idiopathic skeletal hyperostosis. Eur J Radiol. 1998 May;27 (suppl 1):S7-11.[Abstract]

109. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34.[Abstract][Full Text]

110. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012 May;64(5):1388-98.[Abstract]

111. Akar S, Kaplan YC, Ecemiş S, et al. The role of smoking in the development and progression of structural damage in axial SpA patients: a systematic review and meta-analysis. Eur J Rheumatol. 2019 Oct 1;6(4):184-92.[Abstract][Full Text]

112. Kraag G, Stokes B, Groh J, et al. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - a randomized controlled trial. J Rheumatol. 1990 Feb;17(2):228-33.[Abstract]

113. Sharan D, Rajkumar JS. Physiotherapy for ankylosing spondylitis: systematic review and a proposed rehabilitation protocol. Curr Rheumatol Rev. 2017;13(2):121-5.[Abstract]

114. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis andnonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019 Oct;71(10):1599-613.[Abstract][Full Text]

115. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016 Feb;68(2):282-98.[Abstract][Full Text]

116. National Institute for Health and Care Excellence (UK). Spondyloarthritis in over 16s: diagnosis and management. Jun 2017 [internet publication].[Full Text]

117. Millner JR, Barron JS, Beinke KM, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arthritis Rheum. 2016 Feb;45(4):411-27.[Abstract][Full Text]

118. Liang Z, Fu C, Zhang Q, et al. Effects of water therapy on disease activity, functional capacity, spinal mobility and severity of pain in patients with ankylosing spondylitis: a systematic review and meta-analysis. Disabil Rehabil. 2021 Apr;43(7):895-902.[Abstract]

119. Pécourneau V, Degboé Y, Barnetche T, et al. Effectiveness of exercise programs in ankylosing spondylitis: a meta-analysis of randomized controlled trials. Arch Phys Med Rehabil. 2018 Feb;99(2):383-9.[Abstract]

120. Regnaux JP, Davergne T, Palazzo C, et al. Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev. 2019 Oct 2;(10):CD011321.[Abstract][Full Text]

121. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD002822.[Abstract][Full Text]

122. Kasapoglu Aksoy M, Birtane M, Taştekin N, et al. The effectiveness of structured group education on ankylosing spondylitis patients. J Clin Rheumatol. 2017 Apr;23(3):138-43.[Abstract]

123. Hu X, Chen J, Tang W, et al. Effects of exercise programmes on pain, disease activity and function in ankylosing spondylitis: a meta-analysis of randomized controlled trials. Eur J Clin Invest. 2020 Dec;50(12):e13352.[Abstract]

124. Gonzalez-Medina G, Perez-Cabezas V, Marin-Paz AJ, et al. Effectiveness of global postural reeducation in ankylosing spondylitis: a systematic review and meta-analysis. J Clin Med. 2020 Aug 20;9(9):2696.[Abstract][Full Text]

125. Martey C, Sengupta R. Physical therapy in axial spondyloarthritis: guidelines, evidence and clinical practice. Curr Opin Rheumatol. 2020 Jul;32(4):365-70.[Abstract]

126. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28.[Abstract][Full Text]

127. Conroy RM, Pyörälä K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003.[Abstract]

128. Villaverde-García V, Cobo-Ibáñez T, Candelas-Rodríguez G, et al. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: a systematic literature review. Semin Arthritis Rheum. 2017 Apr;46(5):569-83.[Abstract]

129. Chaudhary H, Bohra N, Syed K, et al. All-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2023 May;75(5):1052-65.[Abstract][Full Text]

130. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015 Apr;44(5):551-5.[Abstract]

131. Schieir O, Tosevski C, Glazier RH, et al. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis. 2017 Aug;76(8):1396-404.[Abstract]

132. Bhagavathula AS, Bentley BL, Woolf B, et al. Increased risk of stroke among patients with ankylosing spondylitis: a systematic review and meta-analysis. Reumatol Clin (Engl Ed). 2023 Mar;19(3):136-42.[Abstract]

133. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004 Dec;34(3):585-92.[Abstract]

134. Brophy S, Cooksey R, Atkinson M, et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis - a retrospective cohort study using routine data. Semin Arthritis Rheum. 2012 Oct;42(2):140-5.[Abstract]

135. Bai R, Zhang Y, Liu W, et al. The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis. Angiology. 2019 Jul;70(6):492-500.[Abstract]

136. Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022 Jan;108(1):73-9.[Abstract][Full Text]

137. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun;52(6):1756-65.[Abstract][Full Text]

138. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012 Oct;71(10):1616-22.[Abstract][Full Text]

139. Kroon F, Landewé R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012 Oct;71(10):1623-9.[Abstract]

140. Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952.[Abstract][Full Text]

141. Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016 Aug;75(8):1438-43.[Abstract][Full Text]

142. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8.[Abstract][Full Text]

143. Datto C, Hellmund R, Siddiqui MK. Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses. Open Access Rheumatol Res Rev. 2013 Feb 26;5:1-19.[Abstract][Full Text]

144. Wigand R, Baerwald C, Krause A, et al. 12 years of celecoxib: an inventory. Aktuelle Rheumatologie. 2013;38:38-44.

145. Song IH, Poddubnyy DA, Rudwaleit M, et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008 Apr;58(4):929-38.[Abstract][Full Text]

146. Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis-systematic review and real-world analysis. Rheumatology (Oxford). 2021 Oct 2;60(10):4463-75.[Abstract][Full Text]

147. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014 Nov 27;(11):CD004800.[Abstract][Full Text]

148. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004524.[Abstract][Full Text]

149. Yang Z, Zhao W, Liu W, et al. Efficacy evaluation of methotrexate in the treatment of ankylosing spondylitis using meta-analysis. Int J Clin Pharmacol Ther. 2014 May;52(5):346-51.[Abstract]

150. Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015 Jun;74(6):1241-8.[Abstract]

151. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468.[Abstract][Full Text]

152. Karmacharya P, Duarte-Garcia A, Dubreuil M, et al. Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis. Arthritis Rheumatol. 2020 May;72(5):733-49.[Abstract]

153. Li H, Li Q, Chen X, et al. Anti-tumor necrosis factor therapy increased spine and femoral neck bone mineral density of patients with active ankylosing spondylitis with low bone mineral density. J Rheumatol. 2015 Aug;42(8):1413-7.[Abstract]

154. Siu S, Haraoui B, Bissonnette R, et al. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken). 2015 May;67(6):754-64.[Abstract]

155. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):e3-42.[Abstract][Full Text]

156. Saoussen M, Yasmine M, Lilia N, et al. Tapering biologics in axial spondyloarthritis: a systematic literature review. Int Immunopharmacol. 2022 Nov;112:109256.[Abstract]

157. Uhrenholt L, Christensen R, Dinesen WKH, et al. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2022 Aug 3;61(8):3107-22.[Abstract][Full Text]

158. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007 Oct;66(10):1393-7.[Abstract]

159. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011 Jan;70(1):157-63.[Abstract]

160. Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(3):R117.[Abstract][Full Text]

161. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017 Dec;47(3):343-50.[Abstract][Full Text]

162. Sieper J, van der HD, Dougados M, et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2012 May;71(5):700-6.[Abstract][Full Text]

163. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr;72(4):517-24.[Abstract][Full Text]

164. Deodhar A, Gensler LS, Kay J, et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019 Jul;71(7):1101-11.[Abstract][Full Text]

165. van der Heijde D, Dougados M, Landewé R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017 Sep 1;56(9):1498-509.[Abstract][Full Text]

166. van der Heijde D, Baraliakos X, Hermann KA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018 May;77(5):699-705.[Abstract]

167. Landewé RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020 Jul;79(7):920-8.[Abstract][Full Text]

168. Dougados M, van der Heijde D, Sieper J, et al. Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1590-8.[Abstract][Full Text]

169. Rios Rodriguez V, Hermann KG, Weiß A, et al. Progression of structural damage in the sacroiliac joints in patients with early axial spondyloarthritis during long-term anti-tumor necrosis factor treatment: six-year results of continuous treatment with etanercept. Arthritis Rheumatol. 2019 May;71(5):722-8.[Abstract]

170. Rusman T, van der Weijden MAC, Nurmohamed MT, et al. Is treatment in patients with suspected nonradiographic axial spondyloarthritis effective? Six-month results of a placebo-controlled trial. Arthritis Rheumatol. 2021 May;73(5):806-15.[Abstract][Full Text]

171. Lie E, Lindström U, Zverkova-Sandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017 Sep;76(9):1515-21.[Abstract]

172. Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014 Dec;30(12):2515-21.[Abstract]

173. Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012 May;71(5):661-7.[Abstract][Full Text]

174. van der Heijde D, Deodhar A, Braun J, et al. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014 Jun;41(6):1095-103.[Abstract]

175. Reveille JD, Deodhar A, Caldron PH, et al. Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE study. J Rheumatol. 2019 Oct;46(10):1277-83.[Abstract][Full Text]

176. Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016 Dec;43(12):2120-30.[Abstract]

177. Heldmann F, Baraliakos X, Kiltz U, et al. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90.[Abstract]

178. Elalouf O, Elkayam O. Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag. 2015 Nov 19;11:1719-26.[Abstract][Full Text]

179. Kobayashi S, Yoshinari T. A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis. Mod Rheumatol. 2017 Jan;27(1):142-9.[Abstract]

180. Migliore A, Gigliucci G, Integlia D, et al. Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis. Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):56-64.[Abstract][Full Text]

181. Syversen SW, Goll GL, Jørgensen KK, et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021 May 4;325(17):1744-54.[Abstract][Full Text]

182. Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017 Mar;76(3):571-92.[Abstract]

183. Bilal J, Berlinberg A, Riaz IB, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019 Oct 2;2(10):e1913102.[Abstract][Full Text]

184. Baeten D, Sieper J, Braun J, et al; MEASURE 1 Study Group, MEASURE 2 Study Group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48.[Abstract][Full Text]

185. Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021 Jan;73(1):110-20.[Abstract][Full Text]

186. Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2019 May 1;58(5):859-68.[Abstract][Full Text]

187. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019 Sep 3;5(2):e001005.[Abstract][Full Text]

188. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111.[Abstract][Full Text]

189. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020 Jan 4;395(10217):53-64.[Abstract]

190. Landewé RB, Gensler LS, Poddubnyy D, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis. 2021 May 6;80(8):1022-30. [Abstract][Full Text]

191. National Institute for Health and Care Excellence. Upadacitinib for treating active ankylosing spondylitis. Sep 2022 [internet publication].​[Full Text]

192. National Institute for Health and Care Excellence. Tofacitinib for treating active ankylosing spondylitis. Oct 2023 [internet publication].​[Full Text]

193. Li S, Li F, Mao N, et al. Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis. Eur J Intern Med. 2022 Aug;102:47-53.[Abstract][Full Text]

194. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27;386(4):316-26.[Abstract][Full Text]

195. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002 Oct;61(10):941-2.[Abstract][Full Text]

196. Kemper AR, Van Mater HA, Coeytaux RR, et al. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr. 2012 Mar 15;12:29.[Abstract][Full Text]

197. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005 Oct 5;294(13):1671-84.[Abstract]

198. Burgos-Vargas R, Tse SM, Horneff G, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015 Nov;67(11):1503-12.[Abstract][Full Text]

199. Constantin T, Foeldvari I, Vojinovic J, et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016 Apr;43(4):816-24.[Abstract]

200. Ahmed I, Gertner E. Safety of arthrocentesis and joint injection in patients receiving anticoagulation at therapeutic levels. Am J Med. 2012 Mar;125(3):265-9.[Abstract][Full Text]

201. Bashir MA, Ray R, Sarda P, et al. Determination of a safe INR for joint injections in patients taking warfarin. Ann R Coll Surg Engl. 2015 Nov;97(8):589-91.[Abstract][Full Text]

202. The Primary Care Rheumatology and Musculoskeletal Medicine Society. Joint and Soft Tissue Injection Recommendations. 2021 [internet publication].[Full Text]

203. Dixon WG, Symmons DP, Lunt M, et al; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007 Sep;56(9):2896-904.[Abstract][Full Text]

204. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003 Nov;48(11):3013-22.[Abstract][Full Text]

205. Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(suppl 1):11-34.[Abstract][Full Text]

206. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 Dec;46(12):3151-8.[Abstract][Full Text]

207. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum. 2009 Jun 15;61(6):801-12.[Abstract][Full Text]

208. Chung ES, Packer M, Lo KH, et al; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003 Jul 1;107(25):3133-40.[Abstract][Full Text]

209. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862-9.[Abstract]

210. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009 Dec;68(12):1863-9.[Abstract][Full Text]

211. Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010 Oct;69(10):1756-61.[Abstract]

212. Hou LQ, Jiang GX, Chen YF, et al. The comparative safety of TNF inhibitors in ankylosing spondylitis-a meta-analysis update of 14 randomized controlled trials. Clin Rev Allergy Immunol. 2018 Apr;54(2):234-43.[Abstract]

213. Ma Z, Liu X, Xu X, et al. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis. Medicine (Baltimore). 2017 Jun;96(25):e7145.[Abstract][Full Text]

214. National Institute for Health and Care Excellence (UK). TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Feb 2016 [internet publication].[Full Text]

215. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013 Jan-Feb;31(1):118-21.[Abstract][Full Text]

216. Kumar A. Experience with anti-tumor necrosis factor-alpha therapy in India. APLAR J Rheumatol. 2006 July;9(2):136-41.[Full Text]

217. Provenzano G, Ferrante MC, Simon G. TB screening and anti-TNF alpha treatment. Thorax. 2005 Jul;60(7):613.[Abstract][Full Text]

218. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb;71(2):258-70.[Abstract]

219. Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013 Sep 1;72(9):1475-80.[Abstract]

220. Daunicht WJ. A biophysical approach to the spatial function of eye movements, extraocular proprioception and the vestibulo-ocular reflex. Biol Cybern. 1988;58(4):225-33.[Abstract]

221. Baraliakos X, Deodhar A, Dougados M, et al. Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 Dec;74(12):1943-58.[Abstract][Full Text]

222. van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023 Apr;82(4):515-26.[Abstract][Full Text]

223. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023 Mar;75(3):449-64.[Abstract][Full Text]

224. Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res (Hoboken). 2022 Sep;74(9):1399-408.[Abstract][Full Text]

225. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. [Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.][Abstract][Full Text]

226. Tam LS, Wei JC, Aggarwal A, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019 Mar;22(3):340-56.[Abstract]

227. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.[Abstract][Full Text]

228. Krieckaert CL, van Tubergen A, Gehin JE, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023 Jan;82(1):65-73.[Abstract][Full Text]

229. Nikiphorou E, Santos EJF, Marques A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021 Oct;80(10):1278-85.[Abstract][Full Text]

230. Hamilton L, Barkham N, Bhalla A, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology (Oxford). 2017 Feb;56(2):313-6.[Full Text]

231. Kotsis K, Voulgari PV, Drosos AA, et al. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):857-72.[Abstract]

232. Healey EL, Haywood KL, Jordan KP, et al. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol. 2011 Jan;40(1):34-40.[Abstract]

233. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7):766-71.[Abstract][Full Text]

234. Exarchou S, Lie E, Lindström U, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis. 2016 Aug;75(8):1466-72.[Abstract]

235. Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015 Sep 15;163(6):409-16.[Abstract]

236. Spencer DG, Park WM, Dick HM, et al. Radiological manifestations in 200 patients with ankylosing spondylitis: correlation with clinical features and HLA B27. J Rheumatol. 1979 May-Jun;6(3):305-15.[Abstract]

237. Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 1994 Oct;21(10):1877-82.[Abstract]

238. Zhang M, Li XM, Wang GS, et al. The association between ankylosing spondylitis and the risk of any, hip, or vertebral fracture: a meta-analysis. Medicine (Baltimore). 2017 Dec;96(50):e8458.[Abstract][Full Text]

239. Pray C, Feroz NI, Nigil Haroon N. Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int. 2017 Aug;101(2):182-92.[Abstract]

240. Sweeney S, Gupta R, Taylor G, et al. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol. 2001 Aug;28(8):1862-6.[Abstract]

241. Rosenbaum JT. Characterization of uveitis associated with spondyloarthritis. J Rheumatol. 1989 Jun;16(6):792-6.[Abstract]

242. Kazmierczak J, Peregud-Pogorzelska M, Biernawska J, et al. Cardiac arrhythmias and conduction disturbances in patients with ankylosing spondylitis. Angiology. 2007 Dec-2008 Jan;58(6):751-6.[Abstract]

243. Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, et al. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol. 2006 Mar;25(2):213-8.[Abstract]

244. Mitchell MJ, Sartoris DJ, Moody D, et al. Cauda equina syndrome complicating ankylosing spondylitis. Radiology. 1990 May;175(2):521-5.[Abstract]

245. Tang C, Moser FG, Reveille J, et al. Cauda equina syndrome in ankylosing spondylitis: challenges in diagnosis, management, and pathogenesis. J Rheumatol. 2019 Dec;46(12):1582-8.[Abstract]

246. Breda L, Palazzi C, de Michele G, et al. Spontaneous atlantoaxial subluxation as a presenting manifestation of juvenile ankylosing spondylitis in a female HLA-B27-negative patient. Eur J Pediatr. 2005 Jul;164(7):455-7.[Abstract]

247. Castro MP, Stebbings SM, Milosavljevic S, et al. Construct validity of clinical spinal mobility tests in ankylosing spondylitis: a systematic review and meta-analysis. Clin Rheumatol. 2016 Jul;35(7):1777-87.[Abstract]

248. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Dec;68(12):1811-8.[Abstract]

249. Ledingham J, Gullick N, Irving K, et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2017 Jun 1;56(6):865-8. [Erratum in: Rheumatology (Oxford). 2017 Dec 1;56(12):2257.][Abstract][Full Text]

250. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011 Nov;63(11):3294-304.[Abstract]